CRESCENT BIOPHARMA, INC. — Director's Dealing 2014

Dec 23, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GLYCOMIMETICS INC (GLYC)
CIK: 0001253689
Period of Report: 2014-12-19

Reporting Person: HENOS MICHAEL A (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-12-19	Common Stock	S	10598	$8.6127	Disposed	480113	Indirect
2014-12-22	Common Stock	S	10659	$8.4354	Disposed	469454	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	12562	Direct
Common Stock	22668	Indirect

Footnotes

F1: The common stock was sold in a series of open market transactions on the transaction date with a volume weighted average sale price of $8.6127. The range of sale prices for the transactions reported was $8.51 to $8.78 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F2: Shares are held of record by Alliance Technology Ventures III, L.P. ("ATV III"). The reporting person is a manager of ATV III Partners, LLC, the general partner of ATV III and shares voting and investment power with respect to the securities held by ATV III, but disclaims beneficial ownership of the securities, except to the extent of his pecuniary interest therein.

F3: The common stock was sold in a series of open market transactions on the transaction date with a volume weighted average sale price of $8.4354. The range of sale prices for the transactions reported was $8.00 to $8.645 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.